Mantle Cell Lymphoma Treatment Study
A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission.
This trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
In order to participate you must meet the following criteria:
- Have mantel cell lymphoma.
- Are eligible for an autologous hematopoietic cell transplantation.
- Have completed induction therapy within 60 days prior to preregistration to step 0.
You will be excluded from the study if any of the following criteria apply to you:
- Have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma.
This is a partial list of elgibility requirements.